Bruce Ettinger

Summary

Publications

  1. ncbi request reprint When is it appropriate to prescribe postmenopausal hormone therapy?
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 13:404-10. 2006
  2. ncbi request reprint Vasomotor symptom relief versus unwanted effects: role of estrogen dosage
    Bruce Ettinger
    Am J Med 118:74-8. 2005
  3. ncbi request reprint Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Womens Health (Larchmt) 14:159-71. 2005
  4. ncbi request reprint Making the most of managed care dollars spent for postmenopausal osteoporosis
    Bruce Ettinger
    Department of Medicine, School of Medicine, University of California, San Francisco, USA
    Manag Care Interface 18:55-9. 2005
  5. ncbi request reprint Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Bone Miner Res 19:745-51. 2004
  6. ncbi request reprint Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women
    Alison J Huang
    Veterans Affairs Medical Center, San Francisco, California, USA
    J Bone Miner Res 22:1791-7. 2007
  7. pmc The effects of tibolone in older postmenopausal women
    Steven R Cummings
    San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
    N Engl J Med 359:697-708. 2008
  8. doi request reprint Endometrial effects of tibolone in elderly, osteoporotic women
    Bruce Ettinger
    University of California, San Francisco, San Francisco, California, USA
    Obstet Gynecol 112:653-9. 2008
  9. ncbi request reprint Fracture risk tool validation in an integrated healthcare delivery system
    Joan C Lo
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    Am J Manag Care 17:188-94. 2011
  10. pmc Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study
    Bruce Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    J Clin Densitom 15:334-42. 2012

Detail Information

Publications37

  1. ncbi request reprint When is it appropriate to prescribe postmenopausal hormone therapy?
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 13:404-10. 2006
    ..To develop evidence and consensus-based recommendations for the use of hormone therapy (HT) in postmenopausal women...
  2. ncbi request reprint Vasomotor symptom relief versus unwanted effects: role of estrogen dosage
    Bruce Ettinger
    Am J Med 118:74-8. 2005
    ..Furthermore, healthcare providers need to learn how and when to prescribe lower dosages of HT to optimize patient acceptance and continuation...
  3. ncbi request reprint Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Womens Health (Larchmt) 14:159-71. 2005
    ..To devise, validate, and test a software model that improves how clinicians calculate individual risk for osteoporotic fracture and expected treatment benefit...
  4. ncbi request reprint Making the most of managed care dollars spent for postmenopausal osteoporosis
    Bruce Ettinger
    Department of Medicine, School of Medicine, University of California, San Francisco, USA
    Manag Care Interface 18:55-9. 2005
    ....
  5. ncbi request reprint Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    J Bone Miner Res 19:745-51. 2004
    ..Conversely, previous alendronate treatment reduced the bone marker and BMD response...
  6. ncbi request reprint Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women
    Alison J Huang
    Veterans Affairs Medical Center, San Francisco, California, USA
    J Bone Miner Res 22:1791-7. 2007
    ..This suggests that the protective effects of ultra-low-dose estrogen therapy on the postmenopausal skeletal health may depend critically on women's endogenous estrogen levels before treatment...
  7. pmc The effects of tibolone in older postmenopausal women
    Steven R Cummings
    San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
    N Engl J Med 359:697-708. 2008
    ..Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain...
  8. doi request reprint Endometrial effects of tibolone in elderly, osteoporotic women
    Bruce Ettinger
    University of California, San Francisco, San Francisco, California, USA
    Obstet Gynecol 112:653-9. 2008
    ..To investigate endometrial effects of tibolone administered to postmenopausal women for 3 years...
  9. ncbi request reprint Fracture risk tool validation in an integrated healthcare delivery system
    Joan C Lo
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    Am J Manag Care 17:188-94. 2011
    ..To evaluate the utility of the Fracture Risk Calculator (FRC, Foundation for Osteoporosis Research and Education) for predicting 10-year hip fracture risk within a "real world" population...
  10. pmc Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study
    Bruce Ettinger
    Department of Medicine, University of California, San Francisco, CA, USA
    J Clin Densitom 15:334-42. 2012
    ..01) for major osteoporotic fracture. We conclude that the FRC calibrates well with hip and major osteoporotic fractures observed among older men. Further, addition of BMD to the fracture risk calculation improves the tool's performance...
  11. doi request reprint Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated health care delivery system
    Alice R Pressman
    Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
    J Clin Densitom 14:407-15. 2011
    ..01). Two versions of this risk tool have similar AUROCs, but alternative assessments indicate that addition of BMD improves performance. Multiple methods should be used to evaluate risk tool performance with less reliance on AUROC alone...
  12. ncbi request reprint Use of raloxifene among women with a history of breast cancer
    Laurel A Habel
    Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
    Breast Cancer Res Treat 96:123-9. 2006
    ..To examine raloxifene use among women with a history of breast cancer...
  13. pmc Bone mineral density changes during the menopause transition in a multiethnic cohort of women
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 93:861-8. 2008
    ..Rates of bone loss across the menopause transition and factors associated with variation in menopausal bone loss are poorly understood...
  14. ncbi request reprint Rationale for use of lower estrogen doses for postmenopausal hormone therapy
    Bruce Ettinger
    156 Lombard Street 13, San Francisco, CA 94111, USA
    Maturitas 57:81-4. 2007
    ....
  15. ncbi request reprint High-dose corticosteroid exposure and osteoporosis intervention in adults
    Maggie Che
    Department of Medicine, Kaiser Permanente Medical Center, Vacaville, California 95688 9430, USA
    Ann Allergy Asthma Immunol 97:497-501. 2006
    ..High-dose corticosteroid exposure is associated with increased risk of bone loss and osteoporotic fractures...
  16. ncbi request reprint Predictors of difficulty when discontinuing postmenopausal hormone therapy
    Deborah Grady
    Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
    Obstet Gynecol 102:1233-9. 2003
    ..To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop...
  17. ncbi request reprint Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
    Obstet Gynecol 104:443-51. 2004
    ....
  18. ncbi request reprint Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation
    Deborah Grady
    University of California San Francisco, 1634 Divisadero Street, Suite 600, San Francisco, CA 94115, USA
    Obstet Gynecol 104:837-44. 2004
    ..To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen...
  19. ncbi request reprint Early discontinuation of treatment for osteoporosis
    Anna N A Tosteson
    Department of Medicine, Dartmouth Medical School, Hannover, New Hampshire 03756, USA
    Am J Med 115:209-16. 2003
    ..To identify factors associated with early treatment discontinuation of three agents commonly prescribed for women with low bone density...
  20. doi request reprint Evolution of postmenopausal hormone therapy between 2002 and 2009
    Bruce Ettinger
    University of California, San Francisco, CA, USA
    Menopause 19:610-5. 2012
    ..The objective of this analysis was to assess trends in nationwide hormone therapy prescription claims from 2002 to 2009...
  21. doi request reprint Clinical correlates of atypical femoral fracture
    Joan C Lo
    Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
    Bone 51:181-4. 2012
    ..Reports of atypical femur fracture in bisphosphonate-exposed women have prompted interest in characterizing the clinical profiles of these patients...
  22. ncbi request reprint Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy
    Bruce Ettinger
    Division of Research, Kaiser Permanente Northern California, Oakland, Oakland, California 94611 5714, USA
    Obstet Gynecol 102:1225-32. 2003
    ....
  23. ncbi request reprint Limb fractures in elderly men as indicators of subsequent fracture risk
    Bruce Ettinger
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif 94611, USA
    Arch Intern Med 163:2741-7. 2003
    ..Whether limb fracture in elderly men predicts future fracture is unknown...
  24. ncbi request reprint Comparison of methods to measure low serum estradiol levels in postmenopausal women
    Jennifer S Lee
    San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
    J Clin Endocrinol Metab 91:3791-7. 2006
    ..Accurate measurement of low serum estradiol (E(2) < 30 pg/ml or < 110 pmol/liter) is needed to study relationships between endogenous E(2) and risks of diseases in older women...
  25. ncbi request reprint Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial
    Jeffrey A Tice
    Division of General Internal Medicine, Department of Medicine, University of California, San Francisco 94143, USA
    JAMA 290:207-14. 2003
    ..Dietary supplements containing isoflavones are widely used as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting their efficacy...
  26. ncbi request reprint Tibolone for prevention and treatment of postmenopausal osteoporosis
    Bruce Ettinger
    156 Lombard Street 13, San Francisco, CA 94111, USA
    Maturitas 57:35-8. 2007
    ..Now that fracture efficacy has been added to the list of tibolone's documented bone benefits, physicians must consider this in the overall risks and benefits of its use...
  27. doi request reprint A personal perspective on fracture risk assessment tools
    Bruce Ettinger
    University of California, San Francisco, San Francisco, CA, USA
    Menopause 15:1023-6. 2008
    ..Much more than risk numbers are needed, and, ideally, fracture risk tools should be integrated into bone densitometry reporting or placed into comprehensive, user-friendly, decision aids...
  28. ncbi request reprint Gastric and duodenal safety of daily alendronate
    James G Donahue
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA
    Arch Intern Med 162:936-42. 2002
    ..This study was conducted to estimate the excess risk of hospitalizations for gastric or duodenal perforations, ulcers, and bleeding associated with alendronate use...
  29. doi request reprint Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach
    Bruce Ettinger
    University of California, San Francisco, CA, USA
    Menopause 15:885-9. 2008
    ..To assess the importance and usefulness of self-reported symptom data, especially the most bothersome symptom, in the evaluation of treatment for vulvovaginal atrophy...
  30. ncbi request reprint Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA org
    J Clin Endocrinol Metab 87:3051-6. 2002
    ..Other factors, such as differences in bone accretion, are likely responsible for much of the ethnic variation in adult BMD...
  31. ncbi request reprint Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors
    Joel S Finkelstein
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA org
    J Clin Endocrinol Metab 87:3057-67. 2002
    ..Femoral neck BMD is highest in African-Americans and similar in Chinese, Japanese, and Caucasians. These findings may explain why Caucasian women have higher fracture rates than African-Americans and Asians...
  32. ncbi request reprint Appropriate intervention through fracture risk assessment
    Bruce Ettinger
    Kaiser Permanente Northern California Clinical Professor of Medicine, University of California San Francisco, USA
    Manag Care 14:9-12; discussion 21-3. 2005
  33. ncbi request reprint Effect of isoflavones on lipids and bone turnover markers in menopausal women
    Tamara M Knudson Schult
    Center for Chronic Disease Outcomes Research, Minneapolis VA Medical Center, MN 55417, USA
    Maturitas 48:209-18. 2004
    ..The purpose of this analysis was to compare the effects of two dietary supplements derived from red clover to placebo on lipids and bone turnover markers in symptomatic menopausal women...
  34. ncbi request reprint Hormone predictors of bone mineral density changes during the menopausal transition
    MaryFran R Sowers
    Department of Epidemiology, School of Public Health, University of Michigan, 339 East Liberty Street, Suite 310, Ann Arbor, MI 48104, USA
    J Clin Endocrinol Metab 91:1261-7. 2006
    ..OBJECTIVE AND CONTEXT: Our objective was to examine predictability of reproductive hormone concentrations for bone mineral density (BMD) loss during the menopausal transition...
  35. ncbi request reprint The Classic: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. 1982
    Harry K Genant
    Clin Orthop Relat Res 443:14-8. 2006
  36. ncbi request reprint Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol
    Susan R Johnson
    Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City 52242, USA
    Obstet Gynecol 105:779-87. 2005
    ..To investigate uterine effects of unopposed ultralow-dose transdermal estradiol administered to postmenopausal women for 2 years...
  37. ncbi request reprint For osteoporosis, are two antiresorptive drugs better than one?
    Bruce Ettinger
    J Clin Endocrinol Metab 87:983-4. 2002